Skip to content
Sleep & circadian healthResearch article3 min read

Spanish experts agree on chronic insomnia care, including when daridorexant may fit

MoveVitals Editorial Collective · Study published · Reading updated

Original paper:Comprehensive management of chronic insomnia in Spain: a multidisciplinary modified RAND/UCLA consensus with recommendations on daridorexant. · Frontiers in psychiatry · 2026 · Original paper ↗

Key takeaway

A panel of 7 Spanish experts reached consensus on 36 statements in round one and 37 more in round two, treating chronic insomnia as a distinct disorder driven by hyperarousal and judging daridorexant appropriate across varied patient profiles. This is expert opinion, not trial data, and the topic is a specific drug.

Study design

Research article

Reading basis

Published abstract

Reading focus

Design & applicability

The research question

Chronic insomnia affects daytime life, yet its care is complicated by confusion about what it is, little use of standard diagnostic tools, long benzodiazepine use and under-coding as its own disorder. The authors sought consensus guidance on diagnosing and treating it, including how to use the dual orexin receptor antagonist daridorexant.

Who and how

A multidisciplinary panel of 7 experts used the modified RAND/UCLA Appropriateness Method to evaluate 74 statements on the nature, diagnosis and treatment of chronic insomnia, including daridorexant, across two rating rounds and a structured discussion. Consensus was reached on 36 statements in round one, one statement was removed, and the remaining 37 achieved consensus in round two. The abstract does not describe how experts were chosen.

What it found

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    Experts agreed chronic insomnia is a distinct disorder, with hyperarousal as a central mechanism.
  2. 2
    They stressed targeting daytime functioning and preserving sleep architecture in treatment.
  3. 3
    Daridorexant was considered appropriate across heterogeneous clinical profiles, supported by cited evidence of better nocturnal sleep, daytime functioning and sleep architecture, with favourable tolerability and low abuse potential.
  4. 4
    Overall, the consensus supports a pragmatic, patient-centred approach that combines current evidence with clinical experience.

Limits & uncertainty

  1. 1
    Only 7 experts took part, all in Spain, so the statements reflect a small group's judgement and local practice.
  2. 2
    Consensus means agreement among panellists, not new clinical-trial evidence, and the abstract does not give agreement ratings or the evidence cited for individual statements.
  3. 3
    The topic includes recommendations on one branded-class drug, and the abstract does not state who funded the work or how conflicts of interest were handled. This reading is based on the abstract only.

What to take from it

For people struggling with chronic insomnia, the consensus describes it as a real, separate condition worth assessing with standard tools, not merely a symptom of something else. Whether any medication, including daridorexant, suits you is a decision for you and your clinician.

Reading your own data

Wearables can log sleep duration and regularity, which can help you describe your pattern to a clinician, but sleep-stage estimates are approximate and cannot diagnose insomnia. Use the same device for several weeks, and pair the numbers with how you feel the next day.

How to read this evidence

The index does not establish a precise design. Read the methods before making causal claims; check population, comparator, outcomes and uncertainty in the source.

Authors’ structured abstract English

The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.

Introduction

Chronic insomnia is a prevalent 24-hour disorder with significant daytime impact. Its management is frequently complicated by conceptual barriers, limited use of standardised diagnostic tools and prolonged benzodiazepine use, while insomnia is often overlooked or inadequately coded as an independent disorder. These challenges highlight the need for improved recognition and clearer therapeutic pathways. Dual orexin receptor antagonists (DORAs), particularly daridorexant, offer a new pharmacological option targeting wake-promoting pathways, yet practical guidance on their clinical use remains limited.

Method

A multidisciplinary panel of seven experts conducted a national consensus using the RAND/UCLA Appropriateness Method. Seventy-four statements addressing the nature, diagnosis and treatment of chronic insomnia, including the clinical use of daridorexant, were evaluated across two rating rounds and a structured discussion. Consensus was reached on 36 statements in round one; one statement was removed; and the remaining 37 achieved consensus in round two.

Results

Experts agreed that chronic insomnia is a distinct disorder, with hyperarousal as a central mechanism, and emphasised the importance of targeting daytime functioning and preserving sleep architecture. Daridorexant was considered appropriate across heterogeneous clinical profiles, supported by evidence demonstrating improvements in nocturnal sleep, daytime functioning and sleep architecture, along with favourable tolerability and low abuse potential.

Conclusions

This consensus supports a pragmatic and patient-centred approach to chronic insomnia management, integrating current evidence with expert clinical experience. The recommendations may help guide decision-making in routine practice, including the use of daridorexant when pharmacological treatment is considered appropriate.

Sources & attribution

Comprehensive management of chronic insomnia in Spain: a multidisciplinary modified RAND/UCLA consensus with recommendations on daridorexant.

Álvarez-Ruiz-Larrinaga A, Armenteros L, Bellido C, Triguero LL, Martínez-Raga J, Pascual J, San L.

Frontiers in psychiatry · 2026-10-13

DOI: 10.3389/fpsyt.2026.1927424 ↗PubMed · 42948062 ↗Europe PMC · Recorded licence: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

MoveVitals editorial interpretation · educational content · no individual clinical review recorded

Sources checked 2026-11-01

Practical guides

Read in context

·Trial meta-analysis

Exercise improved sleep-quality scores in adults 45 and older with sleep disorders

Pooling 23 randomized trials with 1,478 adults aged 45 to 77 who had sleep disorders, exercise improved Pittsburgh Sleep Quality Index scores (SMD 0.62, 95% CI 0.40–0.83), and aerobic exercise showed the largest effect in the network analysis (SMD 1.34, 95% CrI 0.86–1.82). Certainty was low to moderate, the outcomes were questionnaires, and the best weekly dose of about 539 MET-min/week is a model estimate, not a prescription.

Journal of Exercise Science & Fitness

In-depth explainersRead study →
·Cohort study

Sleep regularity tracked mortality more closely than sleep duration in 60,977 UK adults

Among 60,977 UK Biobank adults who wore a wrist accelerometer for a week, the most regular fifth of sleepers had a fully adjusted all-cause mortality HR of 0.70 (95% CI 0.59–0.83) against the least regular fifth, over about 6.3 years and 1859 deaths. Regularity fitted the data better than sleep duration, but the study is observational and rests on one week of sleep data.

Sleep

In-depth explainersRead study →
·Randomised trial

Sleep extension cut daily energy intake by about 270 kcal in adults with overweight

In 80 adults with overweight who usually slept under 6.5 hours, two weeks of sleep-extension counselling added about 1.2 hours of sleep and lowered measured energy intake by 270.4 kcal/d versus control (95% CI −393.4 to −147.4). The trial was short, single-centre and in a narrow group, so it does not show lasting weight loss or any benefit for people who already sleep enough.

JAMA Internal Medicine

In-depth explainersRead study →
·Cohort study

Six hours or less of sleep at 50 and 60 linked to higher dementia risk

In 7959 British civil servants followed for about 25 years, sleeping six hours or less at age 50 (HR 1.22, 95% CI 1.01–1.48) or age 60 (HR 1.37, 1.10–1.72) was linked to a higher dementia rate than sleeping seven hours, and persistent short sleep gave an HR of 1.30 (1.00–1.69). Sleep was mostly self-reported and the study is observational, so early brain disease or other factors may explain part of the link.

Nature Communications

In-depth explainersRead study →
Sleep & circadian health →